| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | 0.31 | 1e-05 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.14 | 2e-05 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | 0.14 | 3e-05 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.22 | 3e-05 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.16 | 5e-05 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.14 | 6e-05 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | 0.15 | 8e-05 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.14 | 8e-05 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | 0.13 | 9e-05 |